Fibrostenosis Focused Therapeutics - RFP
Supports research and development of innovative, non-surgical therapies targeting fibrosis in Crohn’s disease and ulcerative colitis, aiming to advance new treatments for fibrotic complications in IBD.
Funder: Crohn's and Colitis Foundation
Due Dates: May 31, 2026 (Preproposal) | June 30, 2026 (Letter of Intent) | August 14, 2026 (Full Proposal)
Funding Amounts: Up to $450,000 per project for one year; renewable for additional years if milestones are met.
Summary: Supports the development of innovative, non-surgical therapeutics targeting fibrosis in IBD patients, with a focus on translational and product-oriented research.
Key Information: Preproposal submission is required before a full proposal; both companies and academic groups with commercialization resources are eligible.
Description
This opportunity from the Crohn's & Colitis Foundation aims to accelerate the development of novel, non-surgical therapeutics addressing fibrostenosis (fibrotic complications) in inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The grant is designed for organizations—either companies or academic groups connected to drug discovery centers—with a strong focus on product discovery, development, and commercialization. Projects should be grounded in clinical observations or published human IBD evidence and are expected to pursue innovative approaches, such as the modulation of specific fibrotic pathways or multidisciplinary strategies. The overarching goal is to fill the significant unmet need for effective therapies to treat or prevent fibrosis in IBD patients, excluding surgical interventions.
